Literature DB >> 4853668

Plasma level profile of haloperidol in man following intramuscular administration.

W A Cressman, J R Bianchine, V B Slotnick, P C Johnson, J Plostnieks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4853668     DOI： 10.1007/bf00561322

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  15 in total

1.  Effect of volume of distribution on plasma levels of total radioactivity.

Authors:  W A Cressman; N L Renzi; A C Bartholomay
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

2.  Haloperidol and trifluperidol in rat adipose tissue.

Authors:  A Bizzi; M T Tacconi; L Airoldi; F Marcucci; E Mussini; S Garattini
Journal:  Rev Eur Etud Clin Biol       Date:  1972-02

3.  Analytical and pharmacokinetic studies on butyrophenones.

Authors:  F Marcucci; E Mussini; L Airoldi; R Fanelli; A Frigerio; F de Nadai; A Bizzi; M Rizzo; P L Morselli; S Garattini
Journal:  Clin Chim Acta       Date:  1971-09       Impact factor: 3.786

4.  A method for the gas chromatographic determination of butyrophenones.

Authors:  F Marcucci; L Airoldi; E Mussini; S Garrattini
Journal:  J Chromatogr       Date:  1971-07-08

5.  Distribution of radioactivity in the tissues of young and adult rats after administration of tritiated haloperidol.

Authors:  R Vertua; A Furlani
Journal:  Eur J Pharmacol       Date:  1968-07       Impact factor: 4.432

6.  A gas chromatographic method for the determination of haloperidol in human plasma.

Authors:  I A Zingales
Journal:  J Chromatogr       Date:  1971-01-06

7.  The distribution of haloperidol in rat brain.

Authors:  R J Naylor; J E Olley
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

8.  Metabolism of haloperidol in the rat. (A preliminary report).

Authors:  G A Braun; C F Kade; E L Roscoe
Journal:  Int J Neuropsychiatry       Date:  1967-08

9.  Absorption and excretion of tritiated haloperidol in man. (A preliminary report).

Authors:  P C Johnson; K D Charalampous; G A Braun
Journal:  Int J Neuropsychiatry       Date:  1967-08

10.  Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat.

Authors:  W Soudijn; I Van Wijngaarden; F Allewijn
Journal:  Eur J Pharmacol       Date:  1967-01       Impact factor: 4.432
View more
  10 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain.

Authors:  R Ohman; M Larsson; I M Nilsson; J Engel; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-09       Impact factor: 3.000

3.  Pharmacokinetics of haloperidol in psychotic patients.

Authors:  Y F Cheng; L K Paalzow; U Bondesson; B Ekblom; K Eriksson; S O Eriksson; A Lindberg; L Lindström
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.

Authors:  R L DesJarlais; G L Seibel; I D Kuntz; P S Furth; J C Alvarez; P R Ortiz de Montellano; D L DeCamp; L M Babé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.

Authors:  M A Moulin; J P Davy; D Debruyne; J C Andersson; M C Bigot; R Camsonne; E Poilpré
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Radioimmunoassay of bromperidol and haloperidol in human and canine plasma.

Authors:  E Van Den Eeckhout; F M Belpaire; M G Bogaert; P De Moerloose
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

Review 8.  Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs.

Authors:  G V Milton; M W Jann
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 9.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

10.  Population pharmacokinetics of haloperidol in terminally ill adult patients.

Authors:  L G Franken; R A A Mathot; A D Masman; F P M Baar; D Tibboel; T van Gelder; B C P Koch; B C M de Winter
Journal:  Eur J Clin Pharmacol       Date:  2017-07-05       Impact factor: 2.953
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.